Biomarkers can help a treatment team to determine the best treatment for a patient, see how the patient is responding, and assist in creating a care plan. New tumor markers are being identified with more frequency, so all tumor markers may not yet be reflected on this list.
- ABCBG
- Cadherin-17 (CDH-17)
- Calretinin-
- CA 11-19
- CA 72-4
- CD 166
- CDC25B Phosphatase
- CEA
- CK20 (Cytokeratin 20) and CK7 (Cytokeratin 7) CK18, CK20
- COX2
- ctDNA
- BRAF V600 mutations
- DPYD
- Ezrin
- GPA33
- HER2 gene amplification or overexpression
- HMGB1
- Insulin-like growth factor binding protein 2 (IGFBP2)
- Ki67
- KRAS
- Microsatellite instability (MSI) and/or mismatch repair deficient (dMMR)
- miR141
- MOC-31/Ep-CAM
- MUC2
- NRAS
- NTRK gene fusion
- Nucleosome
- P53
- PIK3CA
- PKM2
- Programmed death ligand 1 (PD-L1)
- Sidedness
- VEGF
- VIllin